| 000 | 01838 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513051230.0 | ||
| 264 | 0 | _c19940304 | |
| 008 | 199403s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(94)91221-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoldhirsch, A | |
| 245 | 0 | 0 |
_aEffect of systemic adjuvant treatment on first sites of breast cancer relapse. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cFeb 1994 |
||
| 300 |
_a377-81 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Neoplasms _xepidemiology |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 |
_aNeoplasm Metastasis _xprevention & control |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xepidemiology |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTamoxifen _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGelber, R D | |
| 700 | 1 | _aPrice, K N | |
| 700 | 1 | _aCastiglione, M | |
| 700 | 1 | _aCoates, A S | |
| 700 | 1 | _aRudenstam, C M | |
| 700 | 1 | _aCollins, J | |
| 700 | 1 | _aLindtner, J | |
| 700 | 1 | _aHacking, A | |
| 700 | 1 | _aMarini, G | |
| 773 | 0 |
_tLancet (London, England) _gvol. 343 _gno. 8894 _gp. 377-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(94)91221-1 _zAvailable from publisher's website |
| 999 |
_c7904885 _d7904885 |
||